Disarm Therapeutics
AcquiredSt. Louis, United States · Founded 2017 · $30.0M raised
- Headquarters
- St. Louis, Missouri
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- disarmtx.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series ASep 2017
- Rounds
- 1
- Acquisition Date
- Oct 2020
About
Disarm Therapeutics was a biotechnology company developing a new class of disease-modifying therapeutics that block SARM1 to prevent axonal degeneration, a pathological process common to many neurological diseases. Co-founded by Washington University scientists Aaron DiAntonio and Jeffrey Milbrandt, the company closed a $30 million Series A in 2017 and was acquired by Eli Lilly in October 2020, becoming a wholly-owned Lilly subsidiary focused on SARM1 inhibitor drug development.
Summary
Disarm Therapeutics is a Biotech company based in St. Louis, United States, founded in 2017. It has raised $30.0M in total across 1 round, most recently a $30.0M Series A round in Sep 2017. Investors include Eli Lilly, Atlas Venture and Lightstone Ventures.
Funding History
Oct 2020
Sign up to see all 2 events
Funding: Series A. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Specialty pharmaceutical company
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/disarm-therapeutics"><img src="https://indexed.vc/api/badge/company/disarm-therapeutics" alt="Disarm Therapeutics on Indexed.vc" width="260" height="76" /></a>